The largest community of pharma leaders

Novartis, LEO Pharma & MSD discuss what HCPs want – and how you can give it to them

Dear Colleague

Long gone are the days of knocking on doors with a smile and a promise – today, success with HCPs depends on how well you use data insights to create content that feels tailored and trustworthy. But how can you ensure your customer experience offer bucks the one-size-fits-all trend?
eyeforpharma have brought global experts from NovartisLEO Pharma and MSD International together for a webinar to discuss how you can use observational data to build a personalized, value-driven HCP engagement strategy and stay ahead of the competition.

Sign-up to join the free webinar and gain insights on:

  • What HCPs actually want from pharma – what the latest data is telling us, and how current engagement strategies match up
  • The impact of personalized approaches – how you can implement best practice strategies to build stronger relationships
  • Engaging the person and the demographic – which sophisticated data-driven approaches will enable you to exceed the expectations of HCPs as individuals and as a wider collective group
Join these experts on October 10 at 2pm London / 3pm Paris / 9am NY. Sign-up for free here.

If you can’t make it, sign-up anyway and you’ll receive the “on demand” version.

If you have any questions about this webinar, please contact Hannah Brady, Global Projects Director, at eyeforpharma on hbrady@eyeforpharma.com.

Best regards,
Lucy Muñiz MD
Editor The Pharmaceutical Marketing Group
http://magazine.pharmamkt.net

Recent Articles

Reven Pharmaceuticals Reports on the Importance of Micronutrients and Vitamins for COVID-19 in a Prestigious Medical Journal

GOLDEN, Colo.--(BUSINESS WIRE)--Reven Holdings, Inc. (“Reven”), a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment...

Anthony Welters Joins Gilead Sciences’ Board of Directors

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Anthony Welters has been appointed to the company’s Board of Directors. Mr. Welters retired...

AVIA Names Linda Finkel as CEO

CHICAGO--(BUSINESS WIRE)--AVIA, the nation’s leading digital transformation partner for healthcare organizations, announced that its board of directors has appointed AVIA President Linda Finkel to...

Goldfinch Bio Presents Clinical Data from Phase 1 Trial Supporting Advancement of GFB-887 as a Precision Medicine for Patients with Kidney Diseases

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced...

U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the antiviral drug Veklury®...